Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 88.6% in December

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 3,455,246 shares, a growth of 88.6% from the November 30th total of 1,831,825 shares. Currently, 12.9% of the shares of the company are short sold. Based on an average daily trading volume, of 6,402,040 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 6,402,040 shares, the short-interest ratio is presently 0.5 days. Currently, 12.9% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on JSPR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. BTIG Research lowered their target price on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Evercore ISI reduced their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, September 22nd. Finally, JMP Securities dropped their target price on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a report on Monday, September 22nd. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.29.

Jasper Therapeutics Stock Down 3.8%

NASDAQ JSPR traded down $0.07 on Friday, reaching $1.76. The company had a trading volume of 442,419 shares, compared to its average volume of 3,957,529. The company’s fifty day moving average is $1.90 and its 200 day moving average is $2.87. Jasper Therapeutics has a 52-week low of $1.39 and a 52-week high of $22.99. The stock has a market capitalization of $49.24 million, a P/E ratio of -0.30 and a beta of 3.06.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.12). On average, research analysts expect that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in Jasper Therapeutics during the first quarter valued at about $46,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics in the third quarter valued at about $50,000. Marex Group plc bought a new position in shares of Jasper Therapeutics during the 2nd quarter valued at approximately $74,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $78,000. Finally, Two Sigma Investments LP bought a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $96,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.